What roles does Barbara Klencke hold at ALX Oncology related to this Form 3 filing?

Barbara Klencke is identified as an officer of ALX Oncology with the title Chief Medical Officer. The Form 3 serves as her initial statement of beneficial ownership, detailing her stock option awards and common stock positions associated with this executive role.

ALX Oncology CMO Barbara Klencke files Form 3

ALX Oncology Holdings Inc Chief Medical Officer Barbara Klencke filed an initial Form 3 reporting her equity interests in the company.

Accepted by SEC EDGAR 03/05/2026 - 04:01 PM EST

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

ALX Oncology Holdings Inc Chief Medical Officer Barbara Klencke filed an initial Form 3 reporting her equity interests in the company. She lists several stock option awards and common stock positions, reflecting both direct and indirect ownership.

The filing reports stock options over 40,400, 300,000 and 100,000 shares, plus 60,000 common shares held directly and another 60,000 common shares held indirectly by her spouse. Footnotes describe vesting schedules for the options, with installments beginning on February 21, 2025, September 17, 2025, January 31, 2026, June 30, 2026 and February 26, 2026.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Klencke Barbara

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Holding	Stock option (right to buy)	--	--	--
Holding	Stock option (right to buy)	--	--	--
Holding	Stock option (right to buy)	--	--	--
Holding	Common Stock	--	--	--
Holding	Common Stock	--	--	--

Holdings: Stock option (right to buy) — 440,400 contracts (Direct); Common Stock — 60,000 shares (Direct); Common Stock — 60,000 shares (Indirect, See footnote)

Footnotes (4)

F1. The shares are held directly by the reporting person's spouse.
F2. Shares subject to the option vest in 36 equal monthly installments beginning on February 21, 2025.
F3. One-third of the shares subject to the option vest on each of September 17, 2025, January 31, 2026 and June 30, 2026.
F4. Shares subject to the option vest in 12 equal monthly installments beginning on February 26, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider holdings did Barbara Klencke report in ALXO on this Form 3?

Barbara Klencke reported stock options over 40,400, 300,000 and 100,000 ALX Oncology shares, plus 60,000 common shares held directly. She also disclosed an additional 60,000 common shares held indirectly through her spouse as noted in a filing footnote.

How are Barbara Klencke’s ALXO stock options structured and when do they vest?

Her options have time-based vesting schedules. One grant vests in 36 equal monthly installments beginning February 21, 2025. Another vests one-third on each of September 17, 2025, January 31, 2026 and June 30, 2026. A further grant vests in 12 equal monthly installments starting February 26, 2026.

What indirect ALXO ownership did Barbara Klencke disclose on the Form 3?

She disclosed 60,000 ALX Oncology common shares as indirect ownership. A footnote explains these shares are held directly by her spouse. The filing classifies this position as indirect, reflecting that the shares are not held in her own name.

Does Barbara Klencke’s ALXO Form 3 show any insider buying or selling activity?

The Form 3 lists holdings only and does not show insider buying or selling. All entries are coded as holdings with unknown transaction codes, and the transaction summary reports zero buy shares, zero sell shares, and a neutral net buy/sell direction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Klencke Barbara

(Last)

(First)

(Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/25/2026

3. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	60,000	D
Common Stock	60,000	I	See footnote⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock option (right to buy)	⁽²⁾	01/20/2035	Common Stock	40,400	$1.65	D
Stock option (right to buy)	⁽³⁾	09/16/2035	Common Stock	300,000	$1.05	D
Stock option (right to buy)	⁽⁴⁾	01/25/2036	Common Stock	100,000	$1.48	D

Explanation of Responses:

1. The shares are held directly by the reporting person's spouse.

2. Shares subject to the option vest in 36 equal monthly installments beginning on February 21, 2025.

3. One-third of the shares subject to the option vest on each of September 17, 2025, January 31, 2026 and June 30, 2026.

4. Shares subject to the option vest in 12 equal monthly installments beginning on February 26, 2026.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Shelly Pinto, by power of attorney	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR